For over 10 years, Canary has been the only foundation in the world focused solely on early cancer detection. Learn More »
See Canary’s progress in early cancer detection solutions.
|
2000
Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection |
2001
Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage |
2002
Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle |
2003
Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers First Canary science team formed—ovarian cancer |
2004
Canary Foundation formed by Don Listwin |
2005
Second Canary science team formed—pancreatic cancer First annual Scientific Symposium |
2006
Discovery of gene mutation in pancreatic cancer Partnership with Canadian British Columbia Cancer Agency to build antibodies and assays for blood biomarkers |
2007
Two more Canary science teams formed—prostate and lung |
2008
Prostate Active Surveillance Study (PASS) enrolls first patients Canary ovarian team conducts preclinical validation of ovarian biomarker HE4 |
2009
Founded Canary Center at Stanford with Stanford School of Medicine and Stanford Cancer Institute Canary ovarian team launches Novel Markers Trial Magneto-nano sensor developed to detect biomarkers—10,000 times more sensitive than existing tests |
2009Continued
Never Smokers Lung Cancer Study launches Don Listwin named to National Cancer Institute Board of Scientific Advisors |
2010
Lung cancer imaging trial begins at Stanford Stanford team builds photoacoustic device for prostate cancer (begins testing in 2011) Parag Mallick & Sharon Pitteri hired—first full-time faculty at Stanford dedicated 100% to early cancer detection |
2011
Gene fusion discovered for ovarian cancer Canary pancreatic cancer team demonstrates microbubble imaging to below 1 mm in size Canary lung cancer team discovers novel biomarker that defines patients as high-risk |
2012
Breast Cancer Program launched Stanford Cancer Institute Awards Canary Foundation with Spirit of Hope Award |
2013
Stanford moves Canary Center to Stanford’s Technology and Innovation Park—2x lab space Genomic Health partners with PASS team to work on detection test for prostate cancer Microbubble clinical trials in ovarian and breast cancer begin in Rome |
2014
FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford Canary prostate cancer team—PASS wins competitive NCI award Partnership with MD Anderson to build national lung cancer screening trial |
2014Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
|
2014Continued
CRUK launches early cancer detection initiatives in UK OHSU launches billion-dollar early detection initiative |
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform |
2016
Canary Pancreas Team discovers new biomarker candidate for cancer imaging |
2017
Lung cancer biomarker discovered by Canary researchers attracts interest from multiple academic institutions and industry partners who obtain licensing to do further testing |
2018
Canary forges international collaborative partnerships with the University of Calgary and University of Cambridge by funding a series of early detection projects with researchers from both institutions Canary partners with BRCA Foundation to launch new ovarian cancer initiative that examines the link between high-risk factors and early detection |
2019
Launch of multi-institutional Canary High Grade Serous Ovarian Initiative Microbubble technology approved for breast cancer Microbubble approved for pancreatic cancer Completion of first Early Cancer Detection Initiative pilot awards with University of Calgary |
2019Continued
Launch of ACED Alliance – The International Alliance for Cancer Early Detection: partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester |
2019Continued
First jointly funded Early Cancer Detection Conference hosted at Stanford through the Canary Center at Stanford-Knight Cancer Institute at OHSU-Cancer Research UK collaboration |
2020
In Loving Memory Sanjiv Sam Gambhir, MD, PhD |
2021
Milestone enrollment of 2000 men in the Canary Prostate Active Surveillance Study (PASS) |
2022
International Early Detection of Cancer Conference returns to in-person format after 2 years of virtual meetings Canary partnered with Gray Foundation on multiomic analysis of benign fallopian tube tissue to identify early molecular events leading to BRCA-associated High Grade Serous Ovarian Cancer |
2023
Launch of PATROL: Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease Prostate Active Surveillance gene expression profiling study with Veracyte/Decipher begins Pilot study shows pancreas and lesions are visible in the majority of patients using inexpensive Point of Care Ultrasound |
Future Goals
Canary marker remains among the four-marker panel showing mortality reduction benefit for lung cancer First patients imaged with contrast using Point of Care Ultrasound Manufacturing pipeline for microbubbles for early detection established |
Future GoalsContinued
Consensus reached on best practices for Active Surveillance for prostate cancer Multiomic analysis of BRCA vs non-BRCA benign fallopian tubes complete dataset reported Geospatial characterization of fallopian tube precursors of ovarian cancer reported |
|
2000
Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection |
2001
Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage |
2002
Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle |
2003
Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers First Canary science team formed—ovarian cancer |
2004
Canary Foundation formed by Don Listwin |
2005
Second Canary science team formed—pancreatic cancer First annual Scientific Symposium |
2006
Discovery of gene mutation in pancreatic cancer Partnership with Canadian British Columbia Cancer Agency to build antibodies and assays for blood biomarkers |
2007
Two more Canary science teams formed—prostate and lung |
2008
Prostate Active Surveillance Study (PASS) enrolls first patients Canary ovarian team conducts preclinical validation of ovarian biomarker HE4 |
2009
Founded Canary Center at Stanford with Stanford School of Medicine and Stanford Cancer Institute Canary ovarian team launches Novel Markers Trial Magneto-nano sensor developed to detect biomarkers—10,000 times more sensitive than existing tests |
2009 Continued
Never Smokers Lung Cancer Study launches Don Listwin named to National Cancer Institute Board of Scientific Advisors |
2010
Lung cancer imaging trial begins at Stanford Stanford team builds photoacoustic device for prostate cancer (begins testing in 2011) Parag Mallick & Sharon Pitteri hired—first full-time faculty at Stanford dedicated 100% to early cancer detection |
2011
Gene fusion discovered for ovarian cancer Canary pancreatic cancer team demonstrates microbubble imaging to below 1 mm in size Canary lung cancer team discovers novel biomarker that defines patients as high-risk |
2012
Breast Cancer Program launched Stanford Cancer Institute Awards Canary Foundation with Spirit of Hope Award |
2013
Stanford moves Canary Center to Stanford’s Technology and Innovation Park—2x lab space Genomic Health partners with PASS team to work on detection test for prostate cancer Microbubble clinical trials in ovarian and breast cancer begin in Rome |
2014
FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford Canary prostate cancer team—PASS wins competitive NCI award Partnership with MD Anderson to build national lung cancer screening trial |
2014 Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
|
2014 Continued
CRUK launches early cancer detection initiatives in UK OHSU launches billion-dollar early detection initiative |
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform |
2016
Canary Pancreas Team discovers new biomarker candidate for cancer imaging |
2017
Lung cancer biomarker discovered by Canary researchers attracts interest from multiple academic institutions and industry partners who obtain licensing to do further testing |
2018
Canary forges international collaborative partnerships with the University of Calgary and University of Cambridge by funding a series of early detection projects with researchers from both institutions Canary partners with BRCA Foundation to launch new ovarian cancer initiative that examines the link between high-risk factors and early detection |
2019
Launch of multi-institutional Canary High Grade Serous Ovarian Initiative Microbubble technology approved for breast cancer Microbubble approved for pancreatic cancer Completion of first Early Cancer Detection Initiative pilot awards with University of Calgary |
2019 Continued
Launch of ACED Alliance – The International Alliance for Cancer Early Detection: partnership between Cancer Research UK, the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at OHSU, University College London and the University of Manchester |
2019 Continued
First jointly funded Early Cancer Detection Conference hosted at Stanford through the Canary Center at Stanford-Knight Cancer Institute at OHSU-Cancer Research UK collaboration |
2020
In Loving Memory Sanjiv Sam Gambhir, MD, PhD |
2021
Milestone enrollment of 2000 men in the Canary Prostate Active Surveillance Study (PASS) |
2022
International Early Detection of Cancer Conference returns to in-person format after 2 years of virtual meetings Canary partnered with Gray Foundation on multiomic analysis of benign fallopian tube tissue to identify early molecular events leading to BRCA-associated High Grade Serous Ovarian Cancer |
2023
Launch of PATROL: Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease Prostate Active Surveillance gene expression profiling study with Veracyte/Decipher begins Pilot study shows pancreas and lesions are visible in the majority of patients using inexpensive Point of Care Ultrasound |
Future Goals
Canary marker remains among the four-marker panel showing mortality reduction benefit for lung cancer First patients imaged with contrast using Point of Care Ultrasound Manufacturing pipeline for microbubbles for early detection established |
Future Goals Continued
Consensus reached on best practices for Active Surveillance for prostate cancer Multiomic analysis of BRCA vs non-BRCA benign fallopian tubes complete dataset reported Geospatial characterization of fallopian tube precursors of ovarian cancer reported |
